Clinical Trials Browser

OTHER × Lymphoproliferative Disorders × 90 days × Clear all

Lymphoproliferative Disorders, Myeloproliferative Disorders

NCT01555892 2026-03-02

GRALE

Phase 1 Recruiting

136 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders

NCT04996706 2026-02-27

LEO

Enrolling by invitation

21,000 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05898789 2026-02-25

Virtual Rehabilitation for Cancer Survivors

Phase NA Recruiting

388 enrolled

BreastGastrointestinalHead & NeckLymphoid

Breast Carcinoma In Situ, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Lymphoproliferative Disorders, Colorectal Neoplasms

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

514 enrolled

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT01728402 2026-02-17

Pathogenesis of Hematologic Malignancies

Enrolling by invitation

5,000 enrolled

LymphoidMyeloid

Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Phase 2 Active not recruiting

204 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT04858256 2026-01-29

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Phase 2 Recruiting

100 enrolled

Lymphoid

Lymphoproliferative Disorders

NCT06630104 2026-01-08

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Phase NA Recruiting

82 enrolled

LymphoidPlasma cell

Lymphoproliferative Disorders, Multiple Myeloma

NCT02690545 2026-01-06

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Phase 1/2 Active not recruiting

38 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase 1 Active not recruiting

43 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT03467867 2025-12-24

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Phase 2 Active not recruiting

25 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

GRALE

LEO

DETERMINE

Virtual Rehabilitation for Cancer Survivors

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Pathogenesis of Hematologic Malignancies

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL